NRX-101 / NMDA Platform
Post-Traumatic Stress Disorder (PTSD)
Key Facts
About NRx Pharmaceuticals
NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.
View full company profileAbout NRx Pharmaceuticals
NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.
View full company profileTherapeutic Areas
Other Post-Traumatic Stress Disorder (PTSD) Drugs
| Drug | Company | Phase |
|---|---|---|
| EMP-01 (MDMA derivative) | atai Life Sciences | Preclinical |